HIGHLIGHTS
SUMMARY
To verify the response-efficacy prediction of TIS in real-world data, an immunotherapeutic dataset of solid tumors was also dichotomized into the TIS-high and TIS-low groups according to the corresponding regression coefficients of the TIS model. The authors attempted to screen out the HCC tumorigenic and immune infiltration-associated cellular senescence genes through multiple algorithms and thereby constructed an independent prognostic and immune-related signature named TIS incorporating five cellular senescence genes. More research is required to determine the senescence oncology role of TIS genes and to delineate the interaction of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.